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Abstract Phospholipase C beta 1 (PLCβ1) expresses in gli-
omas and cultured glial cells, but its expression is barely de-
tectable in normal glial cells. We analyzed data from Gene
Expression Omnibus (GEO-GDSxxx), The Cancer Genome
Atlas (TCGA), and the Repository for Molecular Brain
Neoplasia Data (REMBRANDT) to explore the potential role
of PLCβ1 as a biomarker in high-grade glioma (HGG).
PLCβ1 expression is significantly higher in grade III gliomas
than that in grade IV gliomas from GDS1815 (n=24 vs. 76),
GDS1962 (n=19 vs. 81), and GDS1975 (n=26 vs. 59). In
GDS1815, PLCβ1 expression correlates with several known
proneural (PN) signature genes; its expression from PN
subtype (n=15) is significantly higher than that from mesen-
chymal (Mes) subtype (n=33) HGG. In GDS1962, PLCβ1
expression is the highest in nontumor brain tissue (n=23)
and is significantly higher than its expression in grade II gli-
omas [astrocytomas (n=7) and oligodendrogliomas (n=37)].
A Kaplan-Meier survival curve from a REMBRANDTcohort
demonstrates that glioma patients with intermediate PLCβ1
expression (n=103) survived significantly longer than PLCβ1
downregulated (2X) groups (n=226). From TCGA data,
PLCβ1 RNA-Seq signal inversely correlates with the patho-
logical grades, and PLCβ1 expression in PN (n=8) is of sig-
nificantly higher levels than that in Mes (n=8) subtypes of
glioblastoma. The top 50 % of PLCβ1 expression subgroup
(n=294) of gliomas (grades II to IV merged) survived signif-
icantly longer than the low 50 percentile of the PLCβ1 ex-
pression subgroup (n=293). p values are less than 0.05 for all
these analyses. We conclude that PLCβ1 is a candidate signa-
ture gene for PN subtype HGG, and its expression inversely
correlates with glioma pathological grade and is a potential
prognostic factor.
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Introduction
Gliomas are the most common primary brain tumors, and the
pathologic grade is the most important factor determining pa-
tients’ prognosis [1, 2]. Originally established by the World
Health Organization (WHO) in 1993 and then updated in
2007, the four-tiered grading system for glioma outlines grade
I as the least aggressive and grade IV as the most aggressive
type of gliomas [3]. Grades I/II and III/IVare also collectively
referred to as low- (LGG) and high-grade gliomas (HGG),
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respectively. Grade IV gliomas, also known as glioblastoma
multiforme (GBM), are the most common and the most ma-
lignant type of primary brain tumor and account for 50–60 %
of all gliomas [4]. Patients can develop gliomas at any age;
however, LGGs are more often found in children and young
adults and HGGs are more prevalent in the elderly. Other
known prognostic factors include patient’s age at initial diag-
nosis, extent of tumor resection, and Karnofsky performance
score [1, 5].
With advancement of molecular biology technology, new
methods for classifying gliomas have emerged in recent years
[6]. The early established methods include gene mutation
analysis and genome-wide screening, which permit identifica-
tion of single or multiple gene abnormalities, epigenetic
changes, and/or chromosomal anomalies [7–9]. The latest de-
velopments, including gene expression profiling, microarray
technique, and whole genome sequencing, are capable of
studying tens of thousands of genes simultaneously.
Previous studies have identified groups of genes being up-
or downregulated within different subtypes of gliomas.
Some gene expression patterns are associated with patient
survival rates [6]. As a result, a new concept of Bsignature^
genes has been introduced to classify HGG based on global
gene transcripts differences [10–12]. For example, two studies
subclassified HGG into three (Mes, PN, and proliferative) and
four (Mes, PN, neuronal, and classical) subtypes, respectively
[10, 11]. Two different sets of signature genes for PN subtypes
were used to separate the PN subtype from the other subtypes:
set 1 of the signature genes for PN subtypes comprised
OLIG2, MAP2, DCX, NeuN, ERBB4, GAD2, etc. and set 2
consisted of OLIG2, ERBB3, SOX2, NKX2-2, DLL3, etc.
[10, 11]. CHI3L1/YKL-40 is used as Mes subtype signature
gene by both studies [10, 11]. Other Mes signature genes
include HLA-G, SERPINE1, CA12, etc. [11]. Strikingly, the
expression of signature genes for PN and Mes subtypes ap-
pears to be mutually exclusive. It is observed that during
GBM progression or recurrence, a unidirectional subclass
shift occurs from PN toward Mes subtype, which represents
a possible common pattern of disease progression [11].
Patients with PN subtype GBM survive longer on average
than those afflicted with other subtypes despite the fact that
PN subtype glioblastoma patients do not benefit significantly
from temozolomide and radiotherapy [10, 11]. Although stud-
ies attempting to classify GBM subtypes do not always use the
same set of signature genes, classification of PN and Mes
subtypes is concordant in almost all related studies [10, 11,
13]. Therefore, it is desirable to identify biomarkers that allow
quick and accurate identification of PN from other subtypes.
The phospholipase C beta 1 (PLCβ1) gene is mapped to
human chromosome 20p12. It is expressed predominantly in
neurons of the central nervous system and is barely detectable
in other tissues or cell types [14–17]. The PLCβ1 protein
catalyzes the formation of inositol 1,4,5-trisphosphate and
diacylglycerol from phosphatidylinositol 4,5-bisphosphate
(PIP2), which plays an important role in the intracellular sig-
nal transduction of extracellular signals, such as metabotropic
glutamate. In rodent brain tissue, PLCβ1 is present in pyra-
midal neurons and interneurons, but is absent in astrocytes by
immunohistochemistry [15, 18, 19]. However, PLCβ1 ex-
pression is detectable in cultured oligodendrocytes and astro-
cytes [20, 21]. In addition, PLCβ1, while absent in freshly
isolated normal glial cells, has been detected in C6 rat glioma
cell lines [21–23].
We hypothesize that PLCβ1 could be a signature gene in
glioma subclassification given its absence in normal glial
cells, yet presence in glioma specimens. In addition, PLCβ1
expression is inducible in primary cultured glial cells [21, 22].
Microarray and RNA Sequencing (RNA-Seq) data, includ-
ing that measuring PLCβ1 expression, was submitted to the
NIH-maintained Gene Expression Omnibus (GEO) and The
Cancer Genome Atlas (TCGA) database [11, 12, 24]. In ad-
dition, GEO dataset-GDS1815, the Repository for Molecular
Brain Neoplasia Data (REMBRANDT, https://caintegrator.
nci.nih.gov/rembrandt), and TCGA databases provide
patient survival information along with PLCβ1 microarray/
RNA-Seq data, both of which allow investigators to perform
survival analysis based on different PLCβ1 expression levels.
In this study, we retrieved data and performed analyses to
determine (1) if PLCβ1 is a candidate signature gene for the
PN subtype glioma, (2) the potential correlation between its
expression and glioma’s pathological grades, and (3) its prog-
nostic value in glioma patients.
Materials and Methods
Ethics Statement
The usage of data and images from the NIH- and TCGA-
maintained databases and from the Human Protein Atlas
(HPA, http://www.proteinatlas.org) in this study meets the
data use policies set by NIH, TCGA, and HPA, respectively.
Access to Online Public Databases
For this study, we used online public databases containing
PLCβ1 microarray and RNA-Seq data, survival data, and im-
munohistochemistry (IHC) results. Microarray data is acces-
sible from NIH-maintained website GEO, which serves as a
public repository for a wide range of high-throughput exper-
imental data. These datasets include single and dual channel
microarray-based experiments measuring messenger RNA
(mRNA) data. GEO staffs have selectively curated GEO se-
ries into a more compact format, GEO dataset (GDSxxxx),
which includes a single spreadsheet of Bfinal^ values and ac-
companying rich sample annotation. Original microarray data
6512 Mol Neurobiol (2016) 53:6511–6525
can be accessed through links provided in Table 1. Three
PLCβ1 probes (213222_at; 215687_x_at; 211925_s_at) are
used in datasets of GDS1815, GDS1962, and GDS1975,
which studied 100, 180, and 85 cases, respectively [11, 12,
25, 26]. GDS2853 dataset used a different probe, 35980_at
PLCβ1 [27].
We also acquired LGG and HGG data (RSEM-normalized
RNA-Seq data) from the Broad Firehose database released on
December 6, 2014 by TCGA. Data from glioma grades II to
IV was merged for analyzing PLCβ1 gene expression; batch
effects were removed by using the distance-weighted discrim-
ination (DWD) method [28]. From the clinical annotations,
we extracted the pathological grades, patient survival status,
and censored data. Glioblastoma subtypes (PN, Mes, classic,
and neuronal or proliferative) were previously determined in
other studies [10].
The REMBRANDT database is in the public domain and
open for researchers. The REMBRANDT website provides
different modes to extract raw data for analysis. These selec-
tions are glioma and its subcategories consisting of astrocyto-
ma, oligodendrogliomas, and GBM. This study focuses on
glioma and its subclass astrocytoma since glioma and astro-
cytoma data contain samples from three (II, III, and IV) path-
ological grades, and they are large sample sizes for analysis.
Oligodendrogliomas and GBM only have two (II and III) and
one (IV) grades, respectively, and their sample sizes are rela-
tively small for analysis. The default setting for Kaplan-Meier
survival plot is based on stratified groups of genes upregulated
≥2.0-folds, downregulated ≥2.0-folds, and at the intermediate
level; reporter type is Affymerix. For a survival plot based on
PLCβ1 gene expression, the default setting selects data gen-
erated from the 213222_at probe because its data has the
h ighe s t geome t r i c mean in t en s i t y. (Note : The
REMBRANDT data portal has been migrated to the
Georgetown Database of Cancer, a knowledge discovery plat-
form which supports access of the data by the scientific
community.)
Human Protein Atlas is a website that enables systematic
analysis of the human proteome using antibody-based prote-
omics and provides images for IHC results in human tissues.
This website permits the utilization and publication of its data
as outlined in its Data Usage Policy (Bthe publication and/or
presentation are solely for informational and non-commercial
purposes^ and Bthe source of the data and/or image is referred
to this site and/or one or more of our publications are cited.^)
Antibody Used in IHC
Based on the information on the HPA website, glioma tissue
was stainedwith four different PLCβ1 antibodies [HPA034743
Table 1 Microarray data retrieved from NIH-maintained GEO databases in this study
Database Contributor Samples Probes Link
GDS1815 [11, 25] Genentech, Inc., South
San Francisco, CA, USA
100 cases
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and HPA057910 (Sigma-Aldrich, St. Louis, MO);
CAB004275 and CAB005334 (Santa Cruz Biotechnology,
Dallas, TX)]. Patient samples were all deidentified and subjects
are listed by ID, gender, age, and pathological grade.
Statistical Analysis
All data is presented as mean values±standard error of the
mean (SEM) in the histograms. Distribution of expression level
was examined by quantile-quantile plot (Q-Q plot) to compare
with normal distribution. Statistical association was measured
by Pearson correlation embedded in Microsoft Excel.
GraphPad Prism (version 6.0; GraphPad Software, San
Diego, CA, USA) was used to generate both a bar graph histo-
gram and a Kaplan-Meier survival plot. We compared the ex-
pression level of PLCβ1 across grades or subtypes with a two-
tailed t test; the log-rank test was used for the Kaplan-Meier
survival plot. A difference was considered to be statistically
significant if the p value was less than 0.05 (i.e., p<0.05) [29].
Results
PLCβ1 Expression Correlates with Other Known PN
Subtype Signature Genes in GDS1815
The GDS1815 dataset contains microarray data generated
from 22,283 gene probes in 100 high-grade glioma samples.
Three probes (213222_at; 215687_x_at; 211925_s_at) were
used to detect PLCβ1 transcripts. Microarray data, presenting
as signal strengths generated by probe 213222_at, is highly
correlated with other two groups of PLCβ1 microarray data
generated by probes 215687_x_at and 211925_s_at.
Correlation scores between microarray data of 213222_at
and 215687_x_at and microarray data of 213222_at and
211925_s_at are 0.73099 and 0.79047, respectively (Table 2
and Supplement Excel file). Data obtained by the 213222_at
probe showed the highest geometric intensity and was chosen
for our data analysis; the REMBRANDT database also uses
this data as default for the Kaplan-Meier survival analysis.
PLCβ1 microarray signal strength also yields a good correla-
tion coefficient with other PN signature genes including
DLL3 (r=0.5), HEY2 (r=0.5), Olig2 (r=0.48), BCAN (r=
0.62), and ERBB4 (r=0.62) [11]. PLCβ1 microarray signal
strength, however, inversely correlates with YKL-40 (r=
−0.59), one commonly used mesenchymal cell marker in
dataset GDS1815.
PLCβ1 Microarray Data Differentiates PN Subtype
from Other HGG Subtypes in GDS1815
Raw data histogram of one PLCβ1 probe (213222_at) is
reproduced from the NIH website (Fig. 1a). The average
PLCβ1 signal strength is significantly lower in Mes (n=33)
than in PN subtypes (n=15) among GBM (p<0.001; Fig. 1b).
Furthermore, PLCβ1 expression results can potentially iden-
tify PN and Mes subtypes, regardless of whether samples are
from primary or recurrent GBMs (Supplement data Figs. S1A
and S1B). In combined samples of grade III and IV gliomas,
the average PLCβ1 signal level in PN subtypes (2642±207,
n=37) is still significantly higher than its level in Mes (852±
120, n=35) and in proliferative subtypes (1242±170, n=28;
both p<0.05). However, PLCβ1 content shows no statistical
difference between Mes and proliferative subtypes (p>0.05;
Fig. 1c).
Validation of PLCβ1 as a PN Subtype Signature Gene
in the TCGA Cohort
In GBM cases from the TCGA cohort, PLCβ1 expression
(RNA-Seq data) is significantly higher in the PN (n=8)
than that in the Mes subtype (n=8; p<0.05; Fig. 2a). While
the difference between glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) expression levels in PN and Mes subtypes
(Fig. 2b) is not statistically significant, GAPDH gene expres-
sion is commonly used as an endogenous control.
PLCβ1 Expression Inversely Correlates with Glioma
Pathological Grades
Known PN subtype signature genes are not only useful in
separating PN from Mes subtypes, but their expression levels
also correlate with different grades of tumors. Bothmicroarray
Table 2 Correlation coefficient between PLCβ1 expression and other
signature genes [11] in GDS1815
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data of ERBB4 (Fig. 1e) and Olig2 (Fig. 1f), two known PN
subtype signature genes, show significantly different expres-
sion levels between grade III and IV gliomas in GDS1815
dataset (p=0.01 and 0.005, respectively). In agreement with
these two signature genes, PLCβ1 (Fig. 1g) also shows a
significantly different expression between grade III (n=24)
and grade IV (n=76) gliomas (p<0.001).
We further validated the relationship between PLCβ1 ex-
pression and gliomas’ pathological grades using other three
independent GEO datasets (GDS2853, GDS1962,
GDS1975). Specifically, GDS2853 studied low- (n=8) and
high-grade (n=6) astrocytomas with 12,625 probes;
GDS1962 studied nontumor controls (n=23), grade II (n=7)
and III (n=19) astrocytomas, GBM (n=81), grade II (n=37)
and III (n=13) oligodendrogliomas with 54,675 probes; and
GDS1975 studied grade III [astrocytes (n=8), mixed
oligoastrocytoma (n=7), oligodendroglioma (n=11)] and
GBM (n=59) with 22,283 probes. DGS1815, GDS1962,
and GDS1975 used the same aforementioned three PLCβ1
probes, and we only did analysis of the data generated using
probe 213222_at.
The GDS2853 gene expression profile revealed that the
signal strength of the signature gene ERBB4 (Fig. 3a), but
not Olig2 (Fig. 3b), was significantly different between low-
grade and high-grade astrocytomas; PLCβ1 data analysis
agrees with ERBB4 in separating low-grade (n=8) and high-
grade (n=6) tumors (Fig. 3c; p=4.0E-4). In comparison,
PLCβ1 raw data shows less variation than that seen in
ERBB4 data.
Among all four GDS datasets, only GDS1962 (Fig. 4a)
contained nontumor samples as controls. Figure 4b shows that







Grade III  Grade IV
B C D
E F G
Fig. 1 a Original microarray data showing PLCβ1 signal strength in
GDS1815 dataset from the NIH website with minor modification. b
Analysis of data from grade IV samples, primary and recurrent tumors
combined. Data shows a significant lower level of PLCβ1 inMes (n=33)
subtypes than in PN (n=15; *p=1.4E-4). cAnalysis of combined samples
of grades III and IV shows that the average PLCβ1 signal level in PN
subtypes (2642±207, n=37) is significantly higher than its level in Mes
(852±120, n=35; p=2.78E-10) and proliferative (Prolif) subtypes (1242
±170, n=28; p=5.14E-6, *p<0.05). The difference between the PLCβ1
signal level in the Mes and proliferative subtype HGG is not statistically
significant (p=0.126). NS nonsignificant. d In primary tumor cases,
pooled data from grade III and grade IV gliomas shows that PLCβ1
microarray signal strengths are significantly higher in patients who sur-
vived over 2 years (mean=240.3 weeks, range 106–477 weeks, n=35)
than those survived less than 2 years (mean=55.4 weeks, range 3–
102 weeks, n=42; *p=0.0035; 23 cases do not have survival data). e–g
ERBB4, Olig2, and PLCβ1 expression, respectively. All of these signal
strengths are significantly lower in grade IV glioma samples (n=76) than
those in grade III gliomas (n=24; *p<0.05)
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the highest in the nontumor controls (n=23), followed by the
grade II (n=7), grade III (n=19), and grade IV (n=81) astro-
cytoma groups (Fig. 4b). The results that average PLCβ1
expression in grade III (n=19) is significantly higher than in
grade IV (n=81) astrocytoma (Fig. 4d; p=0.044) is consistent
with previous analysis. The average PLCβ1 expression in
nontumor controls (n=23) is also significantly higher than in
pooled data of all astrocytoma cases (n=107, p=9.6E-9;
A                                   B
C                                 D
Fig. 2 HGG in TCGA only has a
few cases that are labeled as Mes
and PN subtypes. a Normalized
PLCβ1 expression (RNA-Seq
data) is significantly higher in PN
(n=8) than inMes subtypes (n=8;
*p=4E-4). b In contrast, there is
no statistical difference in
GAPDH expression between PN
and Mes subtypes (p=0.41). c In
the TCGA database, normalized
PLCβ1 expression (RNA-Seq
data) shows significant differ-
ences between grades II (10.87±
0.05; n=212), III (10.23±0.08;
n=231), and IV
(9.61±0.10; n=152; *p<0.0001).
d GAPDH expression shows no
significant difference between
grades III (15.56±0.03) and IV
(15.54±0.05; p=0.68). NS non-
significant. However, grade II
gliomas (15.41±0.03) contain
less GAPDH than grade III
(p=0.017) and grade IV
(p=0.0018; *p<0.05)


















Low-grade        High-grade
Fig. 3 ERBB4, Olig2, and PLCβ1 expressions presented as microarray
data in low- and high-grade astrocytomas (n=14). Original GDS2853
data from the NIH-maintained database are on top of each histogram. a,
b ERBB4 and Olig2 microarray data used to do the same analysis; how-
ever, the ERBB4 signal was significantly reduced in high-grade samples
(*p=0.0037), but the Olig2 signal (p=0.19) was not. c PLCβ1 signal
strength among high-grade astrocytoma samples (n=6) significantly de-
creased in comparison to its signal from low-grade astrocytoma (n=8;
*p=0.0004)
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Fig. 4c). We also analyzed oligodendroglioma cases separately
and found that PLCβ1 expression is inversely related to patho-
logical grades. Grade III (n=13) oligodendroglioma has a sig-
nificantly lower level than that of grade II (n=37, p=7.0E-5;
Fig. S2A). Furthermore, overall oligodendroglioma samples
(n=50) showed significantly higher levels of PLCβ1 than as-
trocytomas (n=107, p=1.4E-6; Fig. S2B). In GDS1975 [12],
PLCβ1 expression was also significantly lower in grade IV (n=
59) than in grade III gliomas (n=26, p=0.3.0E-6; Fig. S3).
Consistent with the outcomes of data analysis using GEO
datasets, PLCβ1 expression level (RNA-Seq data) inversely
correlates with pathological grades (II, III, and IV) in the
TCGA (Fig. 2c), while GAPDH data shows less significant
difference among subtype groups and no significant differ-
ence between grades III and IV (Fig. 2d). GAPDH is com-
monly used as the internal control. Thus, we summarize this
inverse relationship between PLCβ1 expression and glioma
pathological grades in diagram (Fig. 8).
PLCβ1 Expression Is Closely Associated with Patient
Survival in the REMBRANDT Cohort
Gene expression profiling of gliomas has been studied to pre-
dict patient survival [12]. We analyzed the relationship be-
tween PLCβ1 gene expression using probe 213222_at and
patient survival information in the REMBRANDT cohort.
Glioma are stratified into groups based on PLCβ1 expression:
103 cases in the intermediate group, 226 cases in the
downregulated (≥2X) group, and 0 cases in the PLCβ1 up-
regulation (≥2X) group. When analyzing PLCβ1 expression
level in glioma subclass, astrocytoma cases are stratified into
intermediate (n=48) and downregulated (≥2X) groups (n=
57); there is no upregulated group (Fig. 5a, b). Log-rank test
results show significant differences between the intermediate
PLCβ1 group and the PLCβ1 downregulated groups for gli-
oma (p=3.0E-09) and its subclass astrocytoma (p=2.0E-04)
in a Kaplan-Meier survival plot. When PLCβ1 expression is
further stratified as 3X, 4X, 5X, 6X, and 7X downregulation
in glioma cases, log-rank tests still show significant differ-
ences between intermediate and downregulated groups
(Table 4). When PLCβ1 expression is stratified by 3X down-
regulation in astrocytoma cases, the survival curve is still sig-
nificantly different in the intermediate group compared to the
downregulated PLCβ1 groups (p=0.018) (Table 4). GAPDH
expression is normalized internally among all cases (Fig. 5c, d).
Similar to a Kaplan-Meier survival curve for samples of
differential PLCβ1 gene expression, subgroups can also be
stratified by different ERBB4 expression. However, different
levels of ERBB4 expression are only associated with survival
in all glioma cases, but fail to show statistical significance
among glioma subclass astrocytoma cases (Supplement
Figs. S4A and S4B). We also conducted an analysis of a
Kaplan-Meier survival plot for samples with differential
Olig2 gene expression. Olig2 gene expression presents as bi-
directional (up- and downregulation) changes in astrocytoma








Non-tumor    Astrocytoma                          Glioblastoma                                           Oligodendroglioma
NA           II          III                                       IV                                                        II                       III
B C        D
Fig. 4 Analysis of PLCβ1 expression profile fromGDS1962. aOriginal
microarray data copied from the NIH website with minor modification.
NA nonapplicable. b Collective PLCβ1 data analysis. Average PLCβ1
signal from nontumor controls (n=23) is the highest, significantly higher
than low-grade tumors including grade II astrocytomas (n=7, p=
0.00097) and oligodendrogliomas (n=37, p=0.0075). The average
PLCβ1 signal from grade II (n=37) is significantly higher than that from
grade III (n=13) oligodendroglioma (p=7.42E-05). c PLCβ1 signal
levels from nontumor controls (n=23) are significantly higher than those
from astrocytomas cases (Astro, n=107, p=9.63E-09), grades II to IV
combined. d PLCβ1 signal levels from grade III (n=19) astrocytomas
are significantly higher than from grade IV astrocytomas (n=81; *p=
0.044)
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survival outcome among Olig2 gene upregulated (n=62), in-
termediate level (n=33), and downregulated (n=10) sub-
groups (p>0.05) (data not shown).
PLCβ1 Expression Is Closely Associated with Patient
Survival in the TCGA Cohort and GDS1815
The TCGA cohort was also analyzed via a Kaplan-Meier sur-
vival curve based on PLCβ1 expression levels (RNA-Seq
data). In a combination of all cases available from grades II
to IV (n=587), patients in the top 50 % of PLCβ1 expression
group (n=294) survived on average 88.7months, significantly
longer than those of the bottom 50 % percentile of PLCβ1
expression (n=293) who survived on average 21.6 months
(p=4.8E-12; Fig. 6a). In analyzing data solely from GBM
cases, which as a group contains the lowest PLCβ1
expression level, only subjects with top 5 % PLCβ1 expres-
sion (n=9, mean=25.7 months) survive significantly longer
than the lower 95% subjects (n=142, mean=13.2 months, p=
0.039; Fig. 6b). Results from analysis of the top 10 % versus
the rest of the 90 %, and top versus bottom 50 % of PLCβ1
expressions, show no significant survival differences among
GBMs (data not shown).
GDS1815 data can be used to evaluate the prognostic value
of candidate genes because it contains information about pa-
tient age, survival, and tumor grades (Supplement Excel
spread sheet). We found that the patients who died in fewer
than 104 weeks (median duration=55.4 weeks, range 3–
102 weeks, n=42) had a significantly lower level of PLCβ1
than those who survived 104 weeks and longer (median dura-
tion=240.3 weeks, range 106–477 weeks, n=35; Fig. 1d, p=
0.0035). Here we combined grade III and grade IV glioma for
A                                                                     B
C                           D
Fig. 5 Kaplan-Meier survival curve for samples with differential PLCβ1
and GAPDH gene expression, respectively; raw data extracted from the
REMBRANDT cohort. a PLCβ1 downregulated glioma patients (n=
226) had significantly shorter survival times than intermediate level
PLCβ1 glioma patients (n=103) per the log-rank test (p=3.0E-09). b
PLCβ1 downregulated astrocytoma patients (n=57) survived significant-
ly shorter than the intermediate level PLCβ1 astrocytoma patients (n=45)
per the log-rank test (p=2.0E-04). Both databases contain no cases strat-
ified as upregulated PLCβ1 expression (≥2X). c Based on GAPDH ex-
pression level, only 1 glioma case is classified as upregulated (≥2X), not
statistically significant in survival from the group of intermediate level
GAPDH (n=328; p=0.23). There are no GAPDH downregulated glioma
patients (n=0). d Based on the GAPDH expression level, there are no
astrocytoma cases being classified as up- (n=0) or downregulated (n=0)
exceeding 2-fold. Intermediate level of GAPDH is the only group (n=
102). Note: Among the raw data we downloaded for analysis, 14 glioma
cases (include 3 astrocytoma) lacked censored information. Thus, our
analysis has 14 fewer glioma cases (include 3 astrocytoma) than the total
cases reported in the REMBRANDTwebsite (see Table 4)
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data analysis since each subgroup contains only a small num-
ber of cases.
PLCβ1 Expression in Human Glioma Samples
Images from the HPAwebsite show that all four PLCβ1 anti-
bodies stain cortical neurons of their cell bodies and neuropils,
without staining glial cells in normal cerebral cortex (Fig. 7a).
The majority of reports show negative PLCβ1 staining in
glioma cells (Fig. 7b); both HPA057910 and CAB004275
antibodies yield negative staining in glioma cells in 11 glioma
samples (data not shown). Only HPA034743 and
CAB005334 show different intensities of positive staining in
glioma tumor cells. Interestingly, from the same group, all
HPA034743 staining is restricted to nuclei (Fig. 7c), while
all CAB005334 staining is located at cytoplasm and cell mem-
brane (Fig. 7d). We summarize the pathological report from
these 11 patients and PLCβ1 staining in Table 3.
Discussion
Glioma, the collective name for astrocytomas (grades I–IV),
oligodendrogliomas (grades II–III), oligoastrocytomas
(grades II–III), and ependymomas, is the most common pri-
mary brain tumor in adults [30]. Managing of high grade
gliomas, especially GBM, remains a challenge in clinical
practice due to the complexity of the multicellular background
and genetic heterogeneity. We analyzed four independent mi-
croarray datasets from the NIH-maintained GEO databases,
REMBRANDT, and the TCGA database and found that
PLCβ1 gene expression (microarray and RNA-Seq) level is
inversely correlated with gliomas’ pathological grades; it is a
potential novel signature gene in subclassifying HGG into PN
versus other subtypes, and its expression level also correlates
with patients’ survival. Our study provides evidence for the
first time that PLCβ1 is a candidate signature gene for PN
subtype of HGG.
Previous research has highly recommended integrating
molecular findings in current WHO classifications in order
to generate a new histomolecular classification guideline [3,
8]. For instance, promoter methylation status of DNA repair
enzyme O6-methylguanine-DNA methyltransferase
(MGMT), which affects patient chemosensitivity to temozo-
lomide, has become a frequently requested laboratory test in
neuro-oncology [4]. Patients with CpG island hypermethyla-
tion (G-CIMP) and isocitrate dehydrogenase 1 (IDH1) muta-
tion have better prognoses [31, 32]. However, IDH1 mutation
(∼10 %) and G-CIMP methylation positive (∼9 %) only ac-
count for a small percentage of primary GBM [33, 34]. IDH
mutated glioma patients are significantly younger than those
with IDH wild type, and IDH1/2 mutation is strongly associ-
ated with low grade astrocytomas. Paul Mazaris and his col-
leagues demonstrated that none of 31 GBM samples being
tested harbored either IDH1 or IDH2 mutation [35].
Furthermore, studies demonstrated that prognostic signature
genes that work well in long-term GBM survivors who have
IDH mutations have no predictive value in IDH wild-type
cases [36]. Thus, analysis of single gene mutations and/or
epigenetic modifications are useful but have limitations in
clinical practice. Novel classification of gliomas based on gene
expression has shed light to better understanding of glioma
pathogenesis in recent years. For example, Phillips et al. used
35 signature genes to classify 183 GBM samples into three
subtypes: 31 % were PN, 20 % were proliferative, and 49 %
were Mes subtypes. Clinical studies had demonstrated that
patients with tumors displaying PN signature gene markers
live longer, while those tumors have Mes signature genes had
much shorter survival times (174.5 weeks for PN subtypes vs.
65 weeks for Mes subtypes) [11]. Per report by Verhaak and
colleagues, patients with Mes subtypes respond favorably to
standard treatment (temozolomide and radiation) and treatment
A B 
Fig. 6 Kaplan-Meier survival curve for samples with differential PLCβ1
gene expression from the TCGA cohort. a Merged grade II–IV gliomas
are stratified as high (n=294) and low 50 % PLCβ1 expression (n=293).
There is statistical difference in survival between the two groups as
indicated by the log-rank test (p=4.8E-12). b GBM cases are stratified
into the highest 5 % expression (n=9) and the rest of 95% (n=142); there
is statistical difference in survival between the two groups as indicated by
the log-rank test (p=0.039)
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significantly prolonged their survival, but PN subtypes do not
benefit as much from these same treatments [10].
PLCβ has four isoforms, all of which can be detected in the
brain. Only one or two isoforms, however, are predominantly
A                                                             B
C     D
Fig. 7 IHC images obtained from the HPA website. Antibody
CAB005334 is used for images a–c, HPA034743 antibody is used for
d. a PLCβ1 staining from normal cerebral cortex tissue of a 52-year-old
female subject (patient ID—3740). bNegative PLCβ1 staining of glioma
from a 75-year-old male subject (patient ID—2851). Both c and d are
from one 32-year-old female subject (patient ID—122). c Cytoplasmic/
membranous stain of PLCβ1 in glioma cells. dNuclear stain of PLCβ1 in
glioma cells. Bar scale equals to 100 μm
Table 3 Summary of pathology report about PLCβ1 antibodies staining in tumor cells from patients’ glioma IHC (source: Human Protein Atlas http://
www.proteinatlas.org/)
Patient ID Tumor Grade Sex Age CAB005334, Santa Cruz Biotechnology HPA034743, Sigma-Aldrich
Intensity Quantity Location Intensity Quantity Location
122 Low F 32 Weak <25% Cytoplasmic/membranous Moderate 75%-25% Nuclear
2892 Low F 55 Moderate <25% Cytoplasmic/membranous Weak <25% Nuclear
2895 Low M 66 Negative Negative None Weak <25% Nuclear
2909 Low M 43 Weak <25% Cytoplasmic/membranous Weak >75% Nuclear
45 High M 72 Negative Negative None Weak <25% Nuclear
2849 High M 54 Weak <25% Cytoplasmic/membranous Weak <25% Nuclear
2850 High M 54 Negative Negative None Weak 75%-25% Nuclear
2851 High M 75 Negative Negative None Weak 75%-25% Nuclear
2862 High F 40 Negative Negative None Weak 75%-25% Nuclear
2891 High M 49 Negative Negative None Negative Negative None
2907 High M 76 Negative Negative None Weak <25% Nuclear
Note: data is ranked by tumor grade and then patient ID. IHC reports using the other two antibodies (HPA057910 andCAB004275) are not listed because
all results are negative. M male, F female.
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expressed in neurons [16, 37]. PLCβ1, the predominant iso-
form in neurons, is involved in signal transduction in the ce-
rebral cortex and hippocampus via its coupling to the musca-
rinic acetylcholine receptor [38]. It regulates neurogenesis
since the knockout PLCβ1 gene affects cortical barrel forma-
tion in mouse model [18]. The PLCβ1 expression from the
prefrontal cortex of developing human brain displays in an
age-specific manner, suggesting that PLCβ1 is playing an
important role in the differentiation and maturation of neurons
in the developing brain [39]. Oligodendrocytes are also
known to express intermediate levels of PLCβ1; astrocytes
express the lowest level under culture conditions [20]. We
theorize that this outcome is just inducible under culture con-
ditions in vitro because freshly isolated glial cells are negative
of PLCβ1 expression by PCR amplification [21, 22]. Thus,
the finding that PLCβ1 expression was detected in glioma
tissues by different methods such as microarray, RNA-Seq,
and IHC indicates a very meaningful and possibly a patholog-
ical change. Furthermore, PLCβ1 microarray signal strength
correlates well with other PN signature genes including
DLL3, HEY2, Olig2, BCAN, and ERBB4 and negatively
correlates with YKL-40 (Table 2 and Supplement Excel
file), one commonly used mesenchymal cellular marker in
dataset GDS1815. Grouping with the listed PN signature
genes makes PLCβ1 another candidate signature gene for
PN subtype glioma. Most of the microarray studies used three
PLCβ1 probes; the original data generated by three probes in
GDS1815 are highly correlated with one another (Supplement
Excel spread sheet), which confirmed that these probes are of
high specificity and binding efficacy; thus, users can be as-
sured the data is of high reliability.
PLCβ1 gene expression inversely correlate with tumor
grades (III and IV) and survival among glioma patients in
GDS1815 dataset (Fig. 1), the presence of PLCβ1 transcripts
are associated with PN subtype GBM fromMes (Figs. 1b and
2) and proliferative subtypes (Fig. 1c). Average PLCβ1 signal
strength is also useful in separating grade III from grade IV
HGG in GDS1962 (Fig. 4). Average PLCβ1 levels from nor-
mal tissue controls are significantly higher than those from
low-grade tumors and its level is further downregulated in
higher grade tumors, including astrocytomas and
oligodendrogliomas in GDS1962 (Figs. 4 and S2). Because
the TCGA database contains data for GBM as well as grade II/
III gliomas, we merged these data and performed an analysis
after removing batch effects. Normalized PLCβ1 expression
inversely correlates with pathological grades of glioma: the
higher the pathological grade, the lower the PLCβ1 expres-
sion (p<0.0001, Fig. 2c). In contrast, GAPDH data showed no
significant difference between grades III and IV samples,
though grade II samples contain significantly lower amount
of GAPDH than in HGG samples (p<0.05; Fig. 2d).
A Kaplan-Meier survival curve of both REMBRANDT [gli-
oma (Fig. 5a) and astrocytoma (Fig. 5b)] and TCGA data
[grade II to IV merged (Fig. 6a) and GBM (Fig. 6b)] showed
that different subgroups of PLCβ1 microarray/RNA-Seq ex-
pression levels correlate well with patient survival (p<0.05).
It is worth mentioning that only the top 5 % of PLCβ1 expres-
sion (n=9) of GBM cases survived significantly longer than the
rest of 95% of PLCβ1 expression (n=142) (Fig. 6b). However,
the top 10 % and top 50 % PLCβ1 expression groups did not
show survival benefits over the rest (data not shown). We be-
lieve that the GBM group contains the lowest level of PLCβ1
transcripts based on our analysis, but because there are many
other factors affecting PLCβ1 signals (see discussion below), it
is difficult to isolate a subgroup with statistically significantly
Bhigh^ PLCβ1 expression than others. This reason may also
explain why the REMBRANDT cohort analysis shows no sta-
tistical significant difference in survival among GBM cases
(data not shown). ERBB4 expression level also shows unidi-
rectional reduction as PLCβ1 does in the current analysis of the
REMBRANDT cohort. Interestingly, a Kaplan-Meier survival
curve demonstrates statistical significance among the stratified
groups based on PLCβ1 expression in glioma and its subclass
astrocytoma, while a Kaplan-Meier survival curve based on
different ERBB4 expression levels only shows statistical sig-
nificance among stratified glioma cases, but fails to show sta-
tistical significance among astrocytoma cases (Supplement S4).
In GDS1815, when combining data from grade III and IV gli-
oma, PLCβ1 level is significantly different between two groups
of patients: <2 years (n=48) vs. over 2 years survival (n=35)
(Fig. 1d). Thus, this unique application of PLCβ1 gene expres-
sion in predicting patient survival deserves further study in a
large cohort from patients perspectively (Table 4).
PLCβ1 level in gliomas was not only useful in the separation
of low- and high-grade astrocytomas, but also has significant
differences between grades II (low-grade) and III (high-grade)
oligodendrogliomas (Fig. 4b and S4). Okamoto et al. [1] dem-
onstrated that patients with oligodendrogliomas have the highest
survival rate (78 % at 5 years, 51 % at 10 years), followed by
thosewith oligoastrocytomas (70% at 5 years, 49% at 10 years),
and fibrillary astrocytomas (65 % at 5 years, 31 % at 10 years).
Survival of patients with gemistocytic astrocytomas was the
poorest (16 % at 5 years and 0 % at 10 years). Confirming this
observation, our data analysis showed that PLCβ1 signal in
oligodendroglioma is significantly higher than that in pooled data
of astrocytomas (Fig. S2B). A cellular study also demonstrated
that PLCβ1 expression levels in oligodendrocytes were higher
than that in astrocytes [20], a finding that may be useful in
interpreting the clinical outcome whereby oligodendroglioma
patients usually have a better prognosis than astrocytoma pa-
tients. Interestingly, GBMpatients with an oligodendroglial com-
ponent (n=57) who survived longer (12 vs. 5.8 months; p=
0.006), comparing to 50 cases of other primary GBM, showed
no difference in the frequency of common genetic defects, such
as loss of heterozygosity of chromosome 1p/19q, MGMT pro-
moter methylation, or IDH1 mutation [40]. We believe that
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PLCβ1 expression status may provide valuable information in
the scenario when all known biomarkers are unrevealing.
Separate from other known cancer biomarkers, which are usually
upregulated at different stages of a disease, PLCβ1 expression
level is the highest in normal tissues. Glioma samples show
unidirectional reduction regarding PLCβ1 expression—the
higher the pathological grade, the lower the level of PLCβ1
expression (microarray and RNA-Seq data). In addition, the
REMBRANDT database only stratifies brain tumors as PLCβ1
Bintermediate^ and Bdownregulated^ groups, in contrast to most
of the other genes, which usually present as bidirectional chang-
es. There is no subject in the Bupregulated^ group. This raises the
possibility that overall PLCβ1 signal from glioma tumors is
mainly determined by residual neurons, which harbor much
higher levels of PLCβ1 than other cell types. The detected
PLCβ1 level from gliomas is possibly a logical reflection of
residual neurons’ PLCβ1 content, which will diminish as the
tumor cells expand. PLCβ1 originating from glioma cells, if
there is any, only contributes partially tomeasurable PLCβ1 gene
expression.
Gliomas may originate from mixed cell types including ol-
igodendrocytes and astrocytes as well as mesenchymal,
neuroepithelial cells and cancer stem cells. However, the extent
to which each cell type contributes to the overall level of
PLCβ1 detected in patient tumor tissue has not been well stud-
ied. There are reports that glioma cell lines contain detectable
PLCβ1; however, no information is available as to whether
mesenchymal cells, despite being one of the common types
of cells identified in glioma, express PLCβ1. Thus, it will be
necessary to study cellular origins of PLCβ1 expression in
gliomas to determine if different levels of PLCβ1 expression
actually originate from oligodendrocytes, astrocytes, or even
possibly mesenchymal cells versus normal and abnormal
neuroprogenitor cells, or neurons.
Predominantly, cytoplasmic PLCβ1 expression occurs in
neurons and their synapses and neuropils. As a result, abnor-
mal PLCβ1 expression has been studied for its role in neuro-
logical diseases extensively such as seizure and epilepsy [41,
42]. In the analysis of The Catalogue of Somatic Mutations in
Cancer, Mark G. Waugh demonstrated that the change in the
number of gene copies of PLCβ1, as a component of
phosphoinositide pathway, is involved in GBM; however,
their conclusion that GBM cells gain PLCβ1 gene copies is
different from our findings [43].
Accumulating evidence suggests a pathological role of
PLCβ1 in glioma abnormality. Rodent studies showed that
PLCβ1 expression is undetectable by PCR from freshly isolat-
ed astrocytes, but it can be detected in established astrocytoma
cell lines and C6 rat glioma cell lines [15, 20–23]. Interestingly,
PLCβ1 expression is inducible from primary cultured astro-
cytes when stimulated with lipopolysaccharide [22].
Pathological reports from the Human Protein Atlas show that
PLCβ1 antibodies mainly stain neurons and neuropils in a
normal brain without staining glial cells (Fig. 7a) [44].
However, some glioma samples are stained with PLCβ1 anti-
bodies, both cytoplasmic and inside nucleus (Fig. 7c, d). These
stains from human gliomas demonstrate that astrocytes can be
induced to express PLCβ1 under pathological conditions.
PLCβ1 has two (a and b) isoforms which are different in
their C terminals, and both isoforms contain a nuclear localiza-
tion signal domain [45, 46]. Nucleus presence of PLCβ1 was
demonstrated in cortical neurons of rabbit brain [15, 47], and
evidence demonstrated that two isoforms have their preference
in the cytosol and nuclear of C6 glioma cells, respectively [23];
PLCβ1 was also shown to be transited into the nucleus among
C6 glial cell and Neuro2A cell (mouse neuroblastoma cell line)
under stimuli [48]. Inside the nuclear, PLCβ1 is one of the key
molecules that regulate nuclear inositides, and latest research
concludes that nuclear inositides are independently regulated
and nuclear inositol lipids themselves can modulate nuclear pro-
cesses, such as transcription and pre-mRNA splicing, growth,
proliferation, cell cycle regulation, and differentiation [49].
There have been no study found PLCβ1-mediated signaling
in gliomas, and we speculate that PLCβ1 may play a role in
glioma tumorigenesis. It has been demonstrated in hematolog-
ical diseases including myelodysplastic syndromes and leuke-
mia [50, 51] and other neurological diseases [52]. PLCβ1 and
phosphoinositide 3-kinase (PI3K) share the common
Table 4 Kaplan-Meier survival










Glioma (n=343) 2X 0 235 108 3.0E-09
3X 0 163 180 2.5E-08
4X 0 122 221 4.0E-09
5X 0 86 257 3.9E-06
6X 0 69 274 1.6E-05
7X 0 54 289 7.9E-05
Astrocytoma
(n=105)
2X 0 57 48 2.0E-04
3X 0 33 72 0.018
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substrate PIP2. Thus PLCβ1’s activity regulates the availability
of cellular PIP2 content in theory. Upon stimuli, PI3K converts
PIP2 to phosphatidylinositol 3,4,5-trisphosphate (PIP3), which
leads to cascade downstream reaction involving AKT and
mTOR. Evidence exists that PLCβ1 interconnected with
PI3K/AKT/mTOR signaling in solid tumors and hematological
malignancies [49, 53]. In a study of pro-B-lymphoblastic cell, b
isoform PLCβ1 promotes cell survival by affecting AKT acti-
vation, cyclin E expression, and caspase cleavage [54]. In ad-
dition, our analysis demonstrates that PLCβ1 gene expression
level correlates the best with glioma PN signature gene
ERBB4. ERBB4 protein is a tyrosine-protein kinase and a
member of the epidermal growth factor receptor subfamily,
which contributes to glioma pathogenesis. At the protein level,
typical ERBB4 signaling in the central nervous system in-
volves downstream PLC and PI3K-AKT activation; cleaved
intracellular fragment translocates into nucleus and regulates
gene transcription [52]; cleaved ERBB4 protein also plays an
important role in regulating the timing of astrogenesis in the
developing brain [55]. It is worth to mention that ERBB4 ex-
pression is mainly restricted within neurons [56, 57] like
PLCβ1 does among mature rodent brains, not commonly ex-
pressing a high level among astrocytes. It is possible that
ERBB4 and PLCβ1, as neuron predominant proteins, contrib-
ute to glioma tumorigenesis or progression.
As shown in this study, the PLCβ1 signal strength varies
among samples and in the same subgroups. Since microarray
signal strength and RNA sequencing reflects mRNA content
in transcriptome, mRNA stability or instability, different
amount of normal tissue mixed into the tumor samples can
contribute to this. Factors such as tissue sampling and storage
condition, sample processing time lag from initial tissue har-
vesting, treatment regimen (chemo- and radiotherapy) and
time length, primary versus recurrent tumor, tumor patholog-
ical grades, and classification could all contribute to a wide
variation of PLCβ1 expression detected. In addition, PLCβ1
microarray probes only target and bind to common cDNA
region of both a and b isoforms; however, two isoforms are
different in their C terminals; thus, microarray data based on
current PLCβ1 probes could not differentiate the a or b iso-
form. If the transcription of one PLCβ1 isoform is predomi-
nant isoform, the minor component of overall PLCβ1 signal
may not contribute to our conclusion reached in this study: the
higher the glioma grade, the lower the PLCβ1 expression. It
will be possible for one isoform to gain its signal strength
along with pathological grades. More research is certainly
needed to substantiate this observation.
In summary, our data analyses of TCGA and four indepen-
dent GEO datasets revealed an association between differential
expression of PLCβ1 and glioma pathological grades (Fig. 8).
PLCβ1 is a potential novel signature gene for PN subtypes in
molecular classification of HGG because its gene expression
correlates with known PN subtype signature genes; its inducible
property in glial cells further supports its role as a biomarker in
glioma classification. Kaplan-Meier survival curves based on
differential PLCβ1 gene expression from the REMBRANDT
and TCGA cohorts also demonstrate that high level of PLCβ1
expression associates with patient’s long-term survival.
Quantitative PLCβ1 microarray/RNA-Seq result(s) could be
incorporated with current molecular assay tools to supplement
tradiational neuropathology in classifying HGG subtype(s), po-
tentially contributing to glioma patient prognosis andmeasuring
therapy effectiveness.
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Fig. 8 Graphic diagram displays a relationship between glioma PLCβ1
expression and pathological grades. Normal brain (NB) expresses the
highest level of PLCβ1. Among the astrocytomas, the higher the
pathological grade (II to IV), the lower is the PLCβ1 expression. This
inverse relationship also applies to oligodendrogliomas (grades II and III)
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